



Independent Practitioner's Limited Assurance Report to AstraZeneca plc

Report on AstraZeneca plc's Selected Information for the year ending 31 December 2025.

Conclusion

We have performed a limited assurance engagement on whether selected information in AstraZeneca plc's ("AstraZeneca" or the "Company") Sustainability Data Annex for the year ended 31 December 2025 has been properly prepared in accordance with AstraZeneca's Sustainability Reporting Criteria as set out at [Sustainability Data Reporting Criteria 2025](#) (the "Reporting Criteria"). The information within the Report that was subject to assurance is indicated with the symbol "•" (the "Selected Information") (and is also listed in Appendix 1).

Based on the procedures performed and evidence obtained, nothing has come to our attention that causes us to believe that the Selected Information has been properly prepared, in all material respects, in accordance with the Reporting Criteria.

Our conclusion is to be read in the context of the remainder of this report, in particular the "Inherent limitations in preparing the Selected Information" and "Intended use of our report" sections below.

Our conclusion on the Selected Information does not extend to other information that accompanies or contains the Selected Information and our assurance report (hereafter referred to as "Other Information"). We have not performed any procedures with respect to the Other Information.

Basis for conclusion

We conducted our engagement in accordance with the International Standard on Assurance Engagements (UK) 3000 *Assurance Engagements Other Than Audits or Reviews of Historical Financial Information* ("ISAE (UK) 3000") issued by the Financial Reporting Council ("FRC"). Our responsibilities under the standards are further described in the "Our responsibilities" section of our report.

We have complied with the Institute of Chartered Accountants in England and Wales ("ICAEW") Code of Ethics, which includes independence and other ethical requirements founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behaviour, that are at least as demanding as the applicable provisions of the International Ethics Standards Board for Accountants ("IESBA") International Code of Ethics for Professional Accountants (including International Independence Standards).

Our firm applies International Standard on Quality Management (UK) 1 *Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements* ("ISQM (UK) 1"), issued by the FRC, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

Inherent limitations in preparing the Selected Information

The nature of non-financial information; the absence of a significant body of established practice on which to draw; and the methods and precision used to determine non-financial information, allow for different, but acceptable, evaluation and measurement techniques and can result in materially different measurements, affecting comparability between entities and over time.



The Reporting Criteria has been developed to assist AstraZeneca in reporting selected sustainability information in order to measure its progress against its sustainability strategy. As a result, the Selected Information may not be suitable for another purpose.

Directors' responsibilities

The Directors of AstraZeneca are responsible for:

- designing, implementing and maintaining internal controls relevant to the preparation and presentation of the Selected Information that is free from material misstatement, whether due to fraud or error;
- selecting and developing suitable Reporting Criteria for preparing the Selected Information;
- properly preparing the Selected Information in accordance with the Reporting Criteria; and
- the contents and statements contained within the Report and the Reporting Criteria.

Our responsibilities

We are responsible for:

- planning and performing the engagement to obtain limited assurance about whether the Selected Information is free from material misstatement, whether due to fraud or error;
- forming an independent limited assurance conclusion, based on the procedures we have performed and the evidence we have obtained; and
- reporting our conclusion to AstraZeneca.

Summary of the work we performed as the basis for our conclusion

We exercised professional judgment and maintained professional scepticism throughout the engagement. We planned and performed our procedures to obtain evidence that is sufficient and appropriate to obtain a meaningful level of assurance over the Selected Information to provide a basis for our limited assurance conclusion. Planning the engagement involves assessing whether AstraZeneca's Reporting Criteria are suitable for the purposes of our limited assurance engagement. Our procedures selected depended on our judgement, on our understanding of the Selected Information and other engagement circumstances, and our consideration of areas where material misstatements are likely to arise.

In carrying out our engagement, we performed procedures which included:

- conducting interviews with AstraZeneca's management to obtain an understanding of the key processes, systems and controls in place over the preparation of the Selected Information, but did not include evaluating the design of particular control activities, obtaining evidence about their implementation or testing their operating effectiveness;
- performing analytical procedures over the aggregated Selected Information, including a comparison to the prior period's amounts or external information having due regard to changes in business volume and the business portfolio;
- selected limited substantive testing, including agreeing a selection of specific items from the Selected Information to corresponding supporting information including health and safety incident reports and previously reported information where relevant;
- reperforming calculations of the Selected Information for mathematical accuracy and determining whether it is accordance with the Reporting Criteria;



- comparing the number of employees data used to prepare the Selected Information to the Human Resources IT system;
- reading the Report with regard to the Reporting Criteria and for consistency with our findings over the Selected Information.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

Intended use of our report

Our report has been prepared for AstraZeneca solely in accordance with the terms of our engagement. We have consented to the publication of our report on AstraZeneca's website for the purpose of AstraZeneca showing that it has obtained an independent assurance report in connection with the Selected Information.

Our report was designed to meet the agreed requirements of AstraZeneca determined by AstraZeneca's needs at the time. Our report should not therefore be regarded as suitable to be used or relied on by any party wishing to acquire rights against us other than AstraZeneca for any purpose or in any context. Any party other than AstraZeneca who obtains access to our report or a copy and chooses to rely on our report (or any part of it) will do so at its own risk. To the fullest extent permitted by law, KPMG LLP will accept no responsibility or liability in respect of our report to any other party.

Nasrin Moola
for and on behalf of KPMG LLP
Chartered Accountants
15 Canada Square
London
E14 5GL

8 April 2026



Appendix 1: Selected Information

KPI	Unit	Period	Value
Total non-hazardous waste	Tonnes	1 January 2025 to 31 December 2025	15,022
Total hazardous waste	Tonnes	1 January 2025 to 31 December 2025	8,388
Total water use within site water footprint, excluding non-contact cooling water	Million m ³	1 January 2025 to 31 December 2025	3.44
Lost time injury rate	Lost time injuries per million hours worked (Employees)	1 January 2025 to 31 December 2025	0.32
Fatalities	Number of Employees	1 January 2025 to 31 December 2025	0
Fatalities	Number of Contractors	1 January 2025 to 31 December 2025	0